Cargando…

Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy

Serotonin syndrome is a rare but potentially life-threatening adverse drug reaction resulting from the use or overuse of serotonergic medications alone or in combination. Mild symptoms, overlapping features with similar conditions and clinician lack of awareness are the major reasons for an often mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaffney, Ryan R., Schreibman, Ian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464014/
https://www.ncbi.nlm.nih.gov/pubmed/26078731
http://dx.doi.org/10.1159/000382069
_version_ 1782375874796978176
author Gaffney, Ryan R.
Schreibman, Ian R.
author_facet Gaffney, Ryan R.
Schreibman, Ian R.
author_sort Gaffney, Ryan R.
collection PubMed
description Serotonin syndrome is a rare but potentially life-threatening adverse drug reaction resulting from the use or overuse of serotonergic medications alone or in combination. Mild symptoms, overlapping features with similar conditions and clinician lack of awareness are the major reasons for an often missed diagnosis. Not surprisingly, this condition is significantly underreported as a potential complication of endoscopy if serotonergic medications are used periprocedurally for sedation and analgesia. Here we report the case of a patient with relapsed chronic hepatitis C on antidepressant medications who developed signs and symptoms of serotonin syndrome after a percutaneous liver biopsy. Review of the patient's medication list suggested a possible interaction between her home antidepressants and the post-procedure use of fentanyl for abdominal pain. The patient required monitoring in the medical intensive care unit and stabilized after the administration of benzodiazepines and temporary discontinuation of her home medications. We propose that clinicians need to be aware of the increased risk of serotonin syndrome in the outpatient endoscopy setting, particularly with the wider use of serotonergic antidepressants now available and the repeated number of liver biopsies being performed for management of patients with chronic liver disease.
format Online
Article
Text
id pubmed-4464014
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-44640142015-06-15 Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy Gaffney, Ryan R. Schreibman, Ian R. Case Rep Gastroenterol Published online: May, 2015 Serotonin syndrome is a rare but potentially life-threatening adverse drug reaction resulting from the use or overuse of serotonergic medications alone or in combination. Mild symptoms, overlapping features with similar conditions and clinician lack of awareness are the major reasons for an often missed diagnosis. Not surprisingly, this condition is significantly underreported as a potential complication of endoscopy if serotonergic medications are used periprocedurally for sedation and analgesia. Here we report the case of a patient with relapsed chronic hepatitis C on antidepressant medications who developed signs and symptoms of serotonin syndrome after a percutaneous liver biopsy. Review of the patient's medication list suggested a possible interaction between her home antidepressants and the post-procedure use of fentanyl for abdominal pain. The patient required monitoring in the medical intensive care unit and stabilized after the administration of benzodiazepines and temporary discontinuation of her home medications. We propose that clinicians need to be aware of the increased risk of serotonin syndrome in the outpatient endoscopy setting, particularly with the wider use of serotonergic antidepressants now available and the repeated number of liver biopsies being performed for management of patients with chronic liver disease. S. Karger AG 2015-05-06 /pmc/articles/PMC4464014/ /pubmed/26078731 http://dx.doi.org/10.1159/000382069 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: May, 2015
Gaffney, Ryan R.
Schreibman, Ian R.
Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title_full Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title_fullStr Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title_full_unstemmed Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title_short Serotonin Syndrome in a Patient on Trazodone and Duloxetine Who Received Fentanyl following a Percutaneous Liver Biopsy
title_sort serotonin syndrome in a patient on trazodone and duloxetine who received fentanyl following a percutaneous liver biopsy
topic Published online: May, 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464014/
https://www.ncbi.nlm.nih.gov/pubmed/26078731
http://dx.doi.org/10.1159/000382069
work_keys_str_mv AT gaffneyryanr serotoninsyndromeinapatientontrazodoneandduloxetinewhoreceivedfentanylfollowingapercutaneousliverbiopsy
AT schreibmanianr serotoninsyndromeinapatientontrazodoneandduloxetinewhoreceivedfentanylfollowingapercutaneousliverbiopsy